VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Acronyms VEDO-PREDIRESP
- 31 Aug 2018 Biomarkers information updated
- 18 Jul 2018 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020.
- 18 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2019.